Physician profile
Peter E Bloom
NPI 1447468954
$7,439.43
in general payments reported to CMS, 2019-2025
34 companies · $1,625 in 2025
The $1,625 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,559 · 2020: $422 · 2021: $220 · 2022: $629 · 2023: $1,381 · 2024: $1,603 · 2025: $1,625.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,600 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,599.85 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,577.09 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,415.29 | 2019-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $870.13 | 2019-2025 | Gattex, Entyvio, Eohilia |
| Ardelyx, INC. | $513.02 | 2022-2025 | Ibsrela |
| Janssen Biotech, INC. | $392.89 | 2019-2025 | Stelara, Simponi, Simponi Aria |
| Genzyme Corporation | $358.78 | 2023-2025 | |
| Gilead Sciences, INC. | $292.31 | 2019-2025 | |
| Celgene Corporation | $280.21 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $254.91 | 2019-2025 | Ocaliva |
| Madrigal Pharmaceuticals | $250.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Lucid Diagnostics INC. | $167.40 | 2025 | |
| Ironwood Pharmaceuticals, INC | $133.17 | 2019-2024 | Linzess |
| Pfizer INC. | $124.22 | 2019-2024 | |
| Lilly USA, LLC | $103.96 | 2024-2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $96.58 | 2025 | Voquezna |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $89.00 | 2019-2024 | Rebyota |
| Allergan, INC. | $79.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $62.91 | 2019-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $57.77 | 2023-2025 | Dupixent |
| Shire North American Group INC | $48.86 | 2019 | |
| Cook Medical LLC | $37.01 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.01 | 2023 | Cyltezo |
| Qol Medical, LLC | $29.87 | 2019 | |
| Shionogi INC | $25.04 | 2019-2020 | |
| Evoke Pharma, INC. | $20.75 | 2025 | |
| Nestle Healthcare Nutrition INC. | $19.68 | 2023 | |
| Csl Behring | $18.84 | 2023 | Kcentra |
| Endo Pharmaceuticals INC. | $14.97 | 2020 | |
| Alfasigma USA, INC. | $14.76 | 2020 | |
| Redhill Biopharma INC. | $14.60 | 2022 | |
| Braintree Laboratories, INC. | $14.19 | 2024 | Sutab, Suflave |
| Medtronic, INC. | $13.88 | 2025 | Gi Genius |
| Astrazeneca Pharmaceuticals Lp | $11.84 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$77,759.52 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Bloom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.